Navigation Links
ViroPharma to Release 2009 Third Quarter Financial Results on October 28, 2009
Date:10/15/2009

EXTON, Pa., Oct. 15 /PRNewswire-FirstCall/ -- ViroPharma Incorporated's (Nasdaq: VPHM) third quarter financial results for 2009 are expected to be released on Wednesday, October 28, 2009 before the open of the U.S. financial markets.

The company will host a conference call and live audio webcast at 9:00 a.m. Eastern Time on the same day. During the conference call, ViroPharma management will discuss the 2009 third quarter and other business.

The press release and the live webcast of the conference call will be accessible via ViroPharma's corporate website at http://www.viropharma.com. An audio archive will be available at the same address until November 21, 2009. To participate in the conference call, please dial (888) 299-4099 (domestic) and (302) 709-8337 (international). After placing the call, please tell the operator you wish to join the ViroPharma investor conference call.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin®, approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. ViroPharma commercializes Cinryze(TM) (C1 esterase inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. ViroPharma Announces Initiation Of Non-Toxigenic Clostridium Difficile Phase 1 Program
2. ViroPharma Announces Support by Advisory Committee of The Office of Generic Drugs Proposed Guidelines for Developing Generic Versions of Oral Vancomycin Hydorchloride
3. ViroPharma Incorporated Reports Second Quarter 2009 Financial Results
4. ViroPharma to Release 2009 Second Quarter Financial Results on July 29, 2009
5. ViroPharma Announces Appointment of Frank Baldino, Jr., Ph.D. to Board of Directors
6. ViroPharma Announces Meeting of FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology on Bioequivalence Recommendations for Oral Vancomycin Hydrochloride Products
7. ViroPharma to Present at Two May Healthcare Conferences
8. ViroPharma to Present at the Cowen & Company 29th Annual Healthcare Conference
9. ViroPharma to Host Investor Teach-In Educational Symposium on Hereditary Angioedema
10. ViroPharma to Release 2008 Fourth Quarter and Full Year Financial Results on February 24, 2009
11. ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... “ Francis Drake Eyewear ” was ... monthly Biz Report, which reviews and features the latest ... host of NewsWatch and technology expert, conducted the review ... can save users hundreds of dollars while still looking ... company creates fashion-forward glasses that are both stylish and ...
(Date:9/18/2014)... 2014 9Lover.com, an internationally well-known designer ... launched a big promotion for its maternity wedding outfits. ... buy discounted maternity wedding dresses on its ... to all global consumers. The company’s development manager believes ... of ladies delighted. The current special offer will last ...
(Date:9/17/2014)... global ablation technologies market is estimated to grow at ... mature markets (such as the U.S., Germany, France, and ... market in 2014, the Asia-Pacific region is poised to ... next five years.Factors such as increasing government initiatives for ... surgical centers, and the rising focus of international and ...
(Date:9/17/2014)... 18, 2014 IntimateRider, an inventor of ... , has announced that it has entered into a ... Mobility LLC. A primary reason for the deal is ... reach is global. About its sales potential, representatives at ... provide you with the latest products on the market ...
(Date:9/17/2014)... 2014 According to Centers for ... an estimated 173,285 sports- and recreation-related traumatic brain injuries, ... a blood test may be available to help doctors ... recovery will take. , In March of this ... found a way to test blood for a protein ...
Breaking Medicine News(10 mins):Health News:NewsWatch Recently Featured the Fashion-Forward Frames “Francis Drake Eyewear” on National Television 2Health News:Discounted Maternity Wedding Dresses For 2014 Introduced By 9Lover.com 2Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 2Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 3Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 4Health News:IntimateRider Announces All Terrain Medical & Mobility as Its New Dealer 2Health News:IntimateRider Announces All Terrain Medical & Mobility as Its New Dealer 3Health News:Breakthrough blood test will improve concussion diagnoses, treatment 2Health News:Breakthrough blood test will improve concussion diagnoses, treatment 3
... , , , SAN FRANCISCO, ... (ALCMI) today announced the execution of a letter of intent (LOI) ... on molecular diagnostic testing and banking of advanced-stage Lung Cancer tissues. ... http://www.newscom.com/cgi-bin/prnh/20090731/DC55399LOGO ) , , Specific ...
... Survivors of the childhood cancer neuroblastoma are eight times ... to be married, and more likely to have lower ... online July 31 in the Journal of the ... because minimal information exists on the long-term outcomes for ...
... , , TITUSVILLE, N.J., ... approved INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) extended-release injectable suspension for the ... the first once-monthly, long-acting, injectable atypical antipsychotic approved in the ... will market INVEGA SUSTENNA in the U.S. , , ...
... cells or other health conditions are spread, study finds , ... for low-risk cardiac surgery doesn,t appear to increase one,s chances ... , In the study of 1,062 people who required a ... than 80 percent of the patients were still alive a ...
... , GAINESVILLE, Fla., July 31 Sanofi-aventis US ... facial wrinkles in healthy patients in the USA. It offers results ... 7 years of experience with the product while abroad. It was ... Sanofi-aventis is a leading global pharmaceutical company. The FDA approval ...
... , , PHILADELPHIA, July 31 In ... middle class families still won,t be shielded from the crushing burden of ... erode, according to a study published this week in the New ... and David Grande, M.D., M.P.A, of the University of Pennsylvania,s ...
Cached Medicine News:Health News:Addario Lung Cancer Medical Institute Announces Diagnostic Screening and Clinical Research Collaborations With Response Genetics, Inc. 2Health News:Addario Lung Cancer Medical Institute Announces Diagnostic Screening and Clinical Research Collaborations With Response Genetics, Inc. 3Health News:Addario Lung Cancer Medical Institute Announces Diagnostic Screening and Clinical Research Collaborations With Response Genetics, Inc. 4Health News:Long-term health and social outcomes for neuroblastoma survivors 2Health News:FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 2Health News:FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 3Health News:FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 4Health News:FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 5Health News:FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 6Health News:FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 7Health News:FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 8Health News:FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 9Health News:Post-Recession Incomes Will Be Hit Hard by Health Care Spending for Middle Class Working Families, PENN Analysis Shows 2Health News:Post-Recession Incomes Will Be Hit Hard by Health Care Spending for Middle Class Working Families, PENN Analysis Shows 3Health News:Post-Recession Incomes Will Be Hit Hard by Health Care Spending for Middle Class Working Families, PENN Analysis Shows 4
(Date:9/17/2014)... N.J. , Sept. 17, 2014  Bayer HealthCare ... National Hemophilia Foundation,s 66 th Annual Meeting, which ... , D.C.  The data, which will be shared through ... treatment and patient care. Data will be presented in ... research into treatment modalities in hemophilia A patients, Bayer ...
(Date:9/17/2014)... EMERYVILLE, Calif. , Sept. 17, 2014 /PRNewswire/ ... newest data analytics solution that brings complete visibility ... minimize risks in an ever-evolving reimbursement landscape. Powered ... Integrity brings transparency to the critical point between ... operations impact revenue. The solution will improve revenue ...
(Date:9/17/2014)... 2014 Women everywhere know how frustrating a ... uncomfortable, they,re often also embarrassing and have a way ... Support ( http://ph-defense.com ) is a new, over-the-counter product ... homeopathic product. Odor, discharge, and discomfort ... infection. In many cases, the cause of such problems ...
Breaking Medicine Technology:Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 2Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 3Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 4MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 2MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 3New Product from Vireo Systems: pH-D Feminine Health Support 2
... 2011 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) ... to reprise key carfilzomib data presentations that were featured at ... San Diego, California. The teleconference will begin at ... Interested parties may access the teleconference and the presentation that ...
... /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: ... diagnostic ("IVD") company, responded today to the allegations raised ... dated December 6, 2011. The Company maintains that the ... "Report") concern matters which have long been disclosed in ...
Cached Medicine Technology:China Medical Technologies Responds to the Allegations Raised by Glaucus Research Group 2China Medical Technologies Responds to the Allegations Raised by Glaucus Research Group 3China Medical Technologies Responds to the Allegations Raised by Glaucus Research Group 4China Medical Technologies Responds to the Allegations Raised by Glaucus Research Group 5China Medical Technologies Responds to the Allegations Raised by Glaucus Research Group 6
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Medicine Products: